Looking Back at an Eventful Year

December 31, 2025 by Aldevron

Aldevron’s Most-read 2025 Blog Posts

When it comes to the end of the year, it’s good to take a few minutes to reflect on what happened and how it may influence what’s to come in the next year. For Aldevron, it was a very active and momentous year, with the introduction of new products and services, and together with IDT, the successful manufacture of the world’s first personalized CRISPR gene editing drug product to treat an infant with urea cycle disorder (UCD).

Join us as we look back at the most-read 2025 blog posts to see what else happened, and see the groundwork being laid for your future success.

Sequences and Cell-free DNA Technologies: Diving into the fidelity of cell-free DNA
Cell-free DNA manufacturing is an exciting new technology in the cell and gene therapy field. There are promises of lower levels of cell-derived impurities, faster turnaround times, and the ability to handle complex sequences better than traditional E. coli-based manufacturing processes.

Understanding the Risk: The costs of not thinking ahead during early-stage development
The first in a three-part series based on our whitepaper, Set Your Cell and Gene Therapy Program Up for Success from Day One. The complexity and innovative nature of cell and gene therapies (CGT) means they are often discovered and initially developed in academic laboratories, translational institutes, or small biotech startups. These entities typically excel in scientific innovation but can lack experience in later stage development and commercialization.

Rev Up Your R&D: Speed development using the Breakthrough Booster Program
You’re late for an urgent appointment. Traffic is bumper-to-bumper. Your app shows traffic being backed up for miles. Construction ahead is causing a bottleneck that’s slowing everything to a crawl. Anxiety creeps in as you realize how close you are to being late. That’s the driving force behind the Breakthrough Booster Program.

Presentation: Innovative RNA Manufacturing: Breaking Barriers with Mutant T7 Polymerase
For mRNA manufacturing, especially if you are working sequence-to-vial, ensuring that a service provider has the proper capabilities is critical to project success. Aldevron has expanded its end-to-end mRNA services to meet those needs and show its commitment to accelerating mRNA research and development, expanding its capabilities to streamline the entire mRNA manufacturing process.

Webinar On Demand: Revolutionizing mRNA Manufacturing: Introducing AlchemyTM Cell-free DNA Technology
Time. It’s an overriding element therapeutics developers and manufacturers face in the production process. Enter Aldevron’s new Alchemy™ Cell-free DNA technology. In an Outsourced Pharma Capacity Update (OPCU) webinar, Nate Russart, PhD, and Tanner Dockendorf discussed the advantages of Alchemy, a next-generation solution for rapid production of linear DNA template for mRNA manufacturing. This innovative synthetic technology can cut production timelines by over 50%.

Personalized Gene Editing Treatments: A look at the backstory of Baby KJ
With the news of the manufacture of the world’s first mRNA-based personalized CRISPR therapy shared at the 28th ASGCT Annual Meeting, how that success came about has been the subject of many discussions.

Analyze This: Messenger RNA, the revolution in targeted therapies
Messenger RNA (mRNA) technology has rapidly evolved from a laboratory curiosity to a leading force in targeted drug therapies. The remarkable success of mRNA-based COVID-19 vaccines illuminated the immense potential of mRNA-based medicines, ushering in a new era of medical innovation.

Take It from the Top: Planning the path to your destination
It all starts here. The beginning of the line. The beginning of the supply chain. In cell and gene therapy, supply chain planning and management is one of the most crucial aspects that can make or break success.

Presentation: Innovation to Commercialization: CRISPR Medicine Manufacturing Solutions for the Next Decade
With FDA approval of the first CRISPR-based therapeutic in late 2023, and many more programs advancing through trials, demand for genetic medicines are poised to grow substantially in the coming years.

New Frontiers in CRISPR Genome Editing: Enhancing precision through ribonucleoproteins
Since its introduction in 2009, CRISPR-Cas genome editing has represented a monumental leap forward in molecular biology, offering researchers the tools to modify DNA with precision previously deemed unattainable.

• Have questions on this topic? Contact Us
• Visit the Breakthrough Blog page
• Have an idea for a topic? Let us know!

Subscribe to our blog